U.S. Airlines Stock News

MakeMyTrip Limited has released its first-quarter 2026 results, reporting sales of US$151.18 million and total revenue of US$285.58 million, with net income of US$8.35 million for the three months ended June 30, 2026. While revenue increased compared with a year earlier, the fall in net income and earnings per share points to pressure on costs and profitability that may prompt investors to reassess the quality of the company’s growth. We’ll now examine how this revenue growth alongside...

Materion Corporation recently reported past second-quarter 2026 results, with sales rising to US$613.91 million and net income to US$38.76 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. For the first half of 2026, Materion’s sales grew to US$1.16 billion with net income of US$58.13 million, underscoring continued improvement in profitability across its operations. We’ll now explore how Materion’s strong year-over-year sales...

In August 2026, Nabors Industries Ltd. filed an omnibus shelf registration that covers guarantees of debt securities, preferred and common shares, warrants, and debt securities of Nabors Industries, Inc., giving the company the ability to issue a broad range of instruments over time. This filing enhances Nabors Industries’ financial flexibility but also raises questions about how any future capital raising could affect its balance sheet and existing shareholders. We’ll now examine how this...

Westlake Corporation recently reported second-quarter 2026 results, with sales of US$3,271 million and net income of US$260 million, and the board declared a regular second-quarter dividend payable on September 10, 2026. The shift from a net loss in the prior-year quarter to positive earnings per share, alongside 22 years of dividend increases, highlights a meaningful improvement in profitability and ongoing commitment to shareholder returns. We’ll now explore how Westlake’s return to...

Old Second Bancorp (OSBC) is back in focus after recent data highlighted significant market share gains and strong net interest income trends over the past five years, supported by a differentiated product suite and higher non-interest profits. See our latest analysis for Old Second Bancorp. At a share price of $25.91, Old Second Bancorp has seen momentum build, with a 30 day share price return of 9.6% and a 90 day share price return of 24.45%. Over a longer horizon, the 5 year total...

In early August 2026, Airbnb reported second-quarter revenue of US$3,608 million and net income of US$816 million, and issued third-quarter revenue guidance of US$4.69 billion to US$4.77 billion alongside raising its full-year 2026 revenue growth outlook to at least the mid-teens. A key theme from the results was Airbnb’s emphasis on AI-powered product improvements that lifted guest conversion and first-time bookings, particularly among younger travelers, while supporting expansion into...

In the past week, Globus Medical, Inc. reported second-quarter 2026 results showing sales of US$789.61 million, up from US$745.34 million a year earlier, while net income declined to US$151.57 million from US$202.85 million and diluted EPS fell to US$1.10 from US$1.49. Over the first half of 2026, the company grew sales to US$1.55 billion from US$1.34 billion with largely flat net income, and reaffirmed its full-year revenue outlook of US$3.18 billion to US$3.22 billion, highlighting solid...

In August 2026, Evergy, Inc. reported higher sales and earnings for the second quarter and first half of the year, and its Board declared a US$0.6950 per share common dividend payable on September 18, 2026 to shareholders of record on August 18, 2026. This combination of stronger profitability and a maintained cash payout highlights Evergy’s ongoing ability to generate cash while continuing its capital-intensive investment program. Next, we’ll examine how Evergy’s improved quarterly earnings...

AM Best’s recent affirmation of Hanover Insurance Group (THG) subsidiaries’ A financial strength and a+ long term issuer credit ratings, with a stable outlook, has put renewed attention on the stock. See our latest analysis for Hanover Insurance Group. At a share price of $225.29, Hanover Insurance Group has had a 30 day share price return of 5.66% and a 90 day share price return of 14.05%. The 1 year total shareholder return of 35.58% and 3 year total shareholder return of 126.37% point to...

Robert Half (RHI) has closed a long running capital return chapter. The company reported that it has now completed the share repurchase program launched in February 2018, alongside affirming its regular quarterly dividend. See our latest analysis for Robert Half. At a share price of $43.22, Robert Half has seen a 90 day share price return of 65.09% and a year to date share price return of 58.08%, while the 5 year total shareholder return is down 48.82%. This suggests that recent momentum has...

Erasca, Inc. recently reported a wider net loss for the second quarter and first half of 2026, filed a US$112.34 million ESOP-related shelf registration, disclosed a securities class action over its ERAS-0015 program, and appointed veteran oncologist-executive Charles S. Fuchs as president of R&D. Together, these developments highlight a company balancing heavier losses and legal scrutiny with efforts to strengthen its scientific leadership and employee equity incentives. With these updates...

In August 2026, RLJ Lodging Trust reported past second-quarter 2026 results showing higher sales of US$311.76 million and revenue of US$382.99 million, with net income rising to US$31.04 million and diluted EPS from continuing operations improving to US$0.16. Alongside these results, RLJ raised its full-year 2026 net income outlook to a range of US$21.6 million to US$38.6 million, pointing to continued benefits from business travel recovery and recent lifestyle-focused hotel conversions. Now...

Nucleai recently announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead’s global antibody-drug conjugate clinical development programs and generate candidate spatial biomarkers across multiple oncology indications. This partnership highlights how integrating computational pathology with clinical outcomes could strengthen Gilead’s precision oncology efforts and potentially sharpen future biomarker-driven trial...

In August 2026, Ocular Therapeutix reported second-quarter 2026 results showing essentially flat revenue at US$13.48 million year over year, while net loss widened to US$78.76 million and the company also filed an US$81.7 million shelf registration for up to 10,000,000 common shares in an ESOP-related offering. The combination of a larger loss despite slightly improved per-share metrics, alongside preparation for additional equity issuance, raises fresh questions about the company’s funding...

Goldman Sachs Group (GS) has moved into the spotlight after taking a central role in Nvidia’s planned US$500b AI infrastructure financing platform, which aims to turn AI hardware spending into a dedicated, investable asset class. See our latest analysis for Goldman Sachs Group. At a share price of US$1,039.42, Goldman Sachs Group has seen its 90 day share price return rise 9.83%, while the 1 year total shareholder return sits at 45.11%. This points to firm positive momentum rather than a...

Otis Worldwide (OTIS) cut its full year adjusted EPS forecast after higher labor, productivity, and investment costs, along with weaker new equipment demand in China, pressured profitability despite ongoing revenue growth. See our latest analysis for Otis Worldwide. At a share price of $72.63, Otis Worldwide has seen its momentum cool, with the share price return declining 17.78% year to date while the 1 year total shareholder return is down 15.14%. This points to fading optimism as investors...

ArriVent BioPharma (AVBP) drew fresh attention after granting Shanghai Allist Pharmaceuticals exclusive rights to develop and commercialize its antibody drug conjugate ARR-002 in Greater China in return for upfront, milestone, and royalty payments. See our latest analysis for ArriVent BioPharma. Against this licensing backdrop, ArriVent BioPharma’s share price has eased in the short term, with a 1-day share price return of 1.63% down, a 7-day return of 4.31% down, and a 30-day return of...

Toast (TOST) has moved into the spotlight after a series of partnership updates and fresh quarterly results. The latest earnings release sits alongside new agreements with Adyen, Google, and BWH Hotels. See our latest analysis for Toast. The recent partnerships with Adyen, Google, and BWH Hotels, together with Toast's latest quarterly earnings and buyback activity, have coincided with a 53.49% 90 day share price return, even as the 1 year total shareholder return is down 19.47%. This...

Crown Castle (CCI) recently affirmed its income focus, with the Board declaring a quarterly cash dividend of $1.0625 per share. The dividend is payable on September 30, 2026, to stockholders of record on September 15. See our latest analysis for Crown Castle. Crown Castle’s latest dividend decision comes after a tougher share price stretch, with the stock at $75.98 and a 90 day share price return down 15.5% and a 5 year total shareholder return down 51.21%. This signals fading momentum...

In August 2026, Griffon Corporation priced an unregistered US$800 million offering of senior unsecured notes due 2034 at a 6.25% coupon to help redeem its outstanding 5.75% senior notes due 2028, alongside maintaining 2026 revenue guidance of US$1.8 billion and declaring a US$0.22 quarterly dividend. The combination of refinancing its debt stack, ongoing share repurchases totaling US$707.63 million since 2016, and sharply improved quarterly earnings highlights management’s focus on...

Warby Parker (WRBY) is back in focus after its second quarter 2026 earnings release sparked a negative share price reaction, despite reaffirmed full year revenue guidance and plans to increase marketing ahead of an Intelligent Eyewear launch. See our latest analysis for Warby Parker. Against that backdrop, Warby Parker’s share price has eased over the past quarter, with a 90 day share price return of a 9.56% decline contrasting with a 14.54% gain year to date, while the 3 year total...

Alto Neuroscience (ANRO) has moved back into focus after expanding its ALTO-207 program with an additional Phase 3 trial for treatment-resistant depression, supported by fresh funding and independent mechanism-of-action data. See our latest analysis for Alto Neuroscience. The latest ALTO-207 update comes after a period of strong momentum for Alto Neuroscience, with a year-to-date share price return of 93.73% and a 1-year total shareholder return of about 9.2 times an initial investment. The...

Energy driven inflation worries are keeping global bond yields elevated, which keeps real assets like silver squarely on investor radars. When inflation risk feels sticky, investors often look for ways to add exposure to scarce, hard assets without taking on the full volatility of the metal price. This article walks through three stocks from the Top Silver Stocks screener that stand out on quality and cost discipline. The three stocks highlighted below are a starting sample from this theme,...

Coinbase Global has received a Financial Services Permission from Abu Dhabi’s Financial Services Regulatory Authority to establish an international tokenization hub in the ADGM, enabling it to arrange deals in investments and provide custody for fully backed tokenized securities with shareholder rights. The ADGM hub combines securities regulation with blockchain-native and DeFi-composable features, allowing investors to hold tokenized equities directly in wallets while maintaining sanctions...